Abstracts

file

Musuruana M, Koblin B, Lucy D, Ortiz G, McCrossin J, Usher D, Tieu HV. A pilot study comparing sexual risk data collected via smartphone app diaries and online survey questionnaire among at-risk HIV negative men who have sex with men. Poster Presentation, IAS 2017, Paris, France, July 23-26, 2017

Laher F, Bekker LG, Moodie Z, Grunenberg N, Allen M, Cohen K, Frahm N, Malahleha M, Mngadi K, Daniels B, Innes C, Grant S, Yu C, Gilbert P, Phogat S, DiazGranados C, Koutsoukos M, van der Meeren O, Bentley C, Pensiero M, Mehra V, Kublin J, Corey L, Gray GE, Montefiori DC, Morris L, McElrath MJ, Tomaras GD, HVTN 100 Study Team. HVTN 100: The effects of a 12-month booster on immune responses in healthy HIV-uninfected adults vaccinated with ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in South Africa.  Late Breaker Poster Presentation, IAS 2017, Paris, France, July 23-26, 2017

Keystone Symposia

Baxter AE, Morou A, Ballweber-Fleming L, McNevin J, HVTN team, Tomaras G, McElrath MJ, Andersen-Nissen E and Kaufmann DE. Magnitude of HIV vaccine-specific pTfh and non-Tfh response is associated with phenotype skewing and humoral immunity. Poster Presentation, Keystone B Cell and T Follicular Helper Cells Meeting, Whistler, BC, Canada, April 23-27, 2017

Martins KM, Migueles SA, Frahm N, Rosenthal D, Gavil NV, Wang LA, Toulmin SA, Kelly EP, McElrath MJ, Connors M. Low HIV-Specific CD8+ T-Cell Cytotoxic Capacity in Ad5/HIV Vaccinees Is Associated with Reduced Extracellular Levels of Functional Lytic Proteins.  Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Cohen KW, Nelson R, Thayer C, Morris D, De Rosa S, Frahm N, Barnett SW, Montefiori D, Spearman P, Tomaras G, McElrath MJ. Detection of durable vaccine-induced HIV Env-specific memory B cells. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Andersen-Nissen E, Ballweber-Fleming L, Naidoo AF, Harper MS, Fiore-Gartland A, Huang Y, Gray G, McElrath MJ and NIAID HIV Vaccine Trials Network. Systemic innate immune responses in South Africans to the RV144 ALVAC HIV vaccine. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Narpala SR, Prabhakaran M, Astronomo RD, Lemos MP, Westerberg K, Fleming L, Gross M, Ledgerwood JE, McElrath MJ, Mascola J, Koup RA and McDermott AB. Development of a custom ultra-sensitive Singulex Single Molecule Counting (SMC) immunoassay for quantification of VRC01 in serum and mucosal clinical trial samples. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Ditse Z, Mkhize N, Yin M, Keefer M, Montefiori D, Tomaras G, Churchyard G, Karuna S, Morgan C, Bekker LG, Gray G, Mlisana K, Williamson C and Morris L and the NIAID HIV Vaccines Trials Network. Vaccination does not impact development of binding and neutralization responses in HIV-1 breakthrough infections. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Auclair S, Liu F, Churchyard G, Morgan C, Frahm N, Robb M, Kim J, Michael N, Hu H. Distinct HIV susceptibility of different HIV vaccine vector-specific CD4 T cells. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Seaton K et al. Individual-level meta-analysis of HIV-1 Vaccine Elicited Mucosal Antibodies in Human Volunteers. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017


file

Van Tieu H, Lemos M, Andrasik M, Fleming I, Nandi V, Ortiz G, Lucy D, Musuruana M, McElrath MJ, Koblin BA. Acceptability of self-collected rectal swabs for HIV exposure testing among MSM/TGW. Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017

Huang Y, Zhang L, Grunenberg N, Bailer R, Isaacs A, Ledgerwood J, Seaton K, Mayer K, Corey L, Gilbert P. Pharmacokinetics Analysis of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.  Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017

Selinger C, Bershteyn A, Dimitrov DT, Hallett T, Bekker LG, Rees H, Gray G, for the Pox-Protein Public-Private Partnership Global Access Committee. Population-level Impact and Cost-effectiveness of an HIV Vaccine in South Africa. Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017


file

Lemos M, Naidoo A, Fong Y, Fleming L, Mkhize N, Astronomo R, Mukudu H, Lebina L, Martinson N, Ochsenbauer C, Andersen-Nissen E, Morris L, McElrath MJ. Broadly Neutralizing Antibodies can Prevent HIV infection in Foreskin Ex-vivo Explant Infection Models. Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Buchbinder S, Grunenberg N, Sanchez B, Seaton K, Ferrari G, Moody MA, Frahm N, Montefiori D, Goepfert P, Baden L, Hay C, Yu X, Gilbert P, McElrath MJ, Huang Y, Robinson H, Tomaras G, HVTN 094 Study Group. DNA/MVA HIV vaccine producing virus-like particles (VLPs) is well-tolerated and induces durable functional antibodies (Abs) in HVTN 094. Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Huang Y, Tomaras G, Andersen-Nissen E, Dintwe O, Morris L, Grunenberg N, Isaacs A, DiazGranados C, Sinangil F, Laher F, Swann E, DeRosa S, Ferrari G, Montefiori D, Gilbert PB, McElrath MJ, Corey L, Gray GE. The relationship between immune responses to tetanus vaccine, hepatitis B vaccine and a pox-protein HIV vaccine regimen. Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Astronomo RD, Lemos MP, Narpala S, Czartoski J, Westerberg K, Fleming L, Gross M, Tieu HV, Baden L, Lederman M, Hammer S, Frank I, Ochsenbauer C, Grunenberg N, Ledgerwood JE, McDermott A, Mayer K, McElrath MJ. Rectal and Vaginal Biopsies from Men and Women Infused Intravenously with VRC01 Show Protection in Ex Vivo HIV-1 Challenge. Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Rouphael N, Morgan C, Li S, Jensen R, Sanchez B, Swann E, De Rosa S, Keefer MC. DNA and Protein Co-administration Elicits Higher HIV-specific nAb and Comparable CD4+ T-cell Responses as Traditional Prime/Boost Regimens (HVTN 105).  Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Graham B, Roederer M, Michael NL, Robb ML, McElrath MJ, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB and the HVTN505 sieve analysis team. Sieve Pressure toward the CD4 Binding Site of Env in HVTN 505 Breakthrough Infections. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016.

Janes H, Cohen K, Sobieszczyk M, Frahm N, Karuna S, Sanchez B, Magaret C, Adams E, Hammer S, Gilbert PB, McElrath MJ. Vaccine-induced CD8+ T Cell Immunity Strongly Predicts  Lower HIV Infection Risk in HVTN 505.  Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Hural J, Metch B, Grunenberg N, Allen M, Coombs R, Dragavon J, Puren A, Singh B, Maenza J, and the NIAID HIV Vaccine Trials Network. HIV Vaccine Trials Network (HVTN) 910: Long-term follow-up of HIV Vaccine-Induced Seropositivity (VISP) among HIV Vaccinees. Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016 

Dietrich J, Lazarus E, Andrasik MP, Morgan C, Isaacs AJ, Huang Y, Laher F, Kublin J, Gray GE for the HVTN 915 study team. A mobile health (mHealth) application feasibility study to collect sexual risk information among young women from Soweto, South Africa. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016.

Morgan C, Lazarus E, Lemos M, Huang Y, Isaacs A, Laher F, Hural J, Dietrich J, Chung E, Coombs R, Gray G, Kublin J. High Adherence to Daily Vaginal Swabs and Reliable Sexual Behavior Reporting via Mobile Phone App for Assessing HIV Virion Exposure (HVTN 915). Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Selinger C, Bershteyn A, Wood D, Gilbert PB, Dimitrov D. Population-level Impact of an ALVAC/AIDSVAX Vaccine Augmented with Additional Booster through Targeted Campaigns in South Africa. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016.

de Montigny S, Mâsse BR, Wood D, Gilbert PB, Dimitrov DT. Assessing the Impact of the Vaccine Efficacy Profile and Regimen Adherence on Projected Effectiveness of the HVTN 702 Vaccine Regimen in South Africa. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Morgan C, Ramirez S, Karg C, Andrew P, Gray G, Bekker LG, Corey L, Hural J, Lazarus E, Dunbar D, Gray B, Premrajh A, Crida D, Laher F, Malahleha M, Grunenberg N, Andriesen J, Karuna S, Harden D, van der Ven M. Applying Lean Thinking and Rapid Process Improvement to Multiple Global HIV Vaccine Trial Operations. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Andrasik M, Broder G, Oseso L, Norwood A. Utilizing a Community-Based Participatory Research Approach to Develop Animated Videos for Community Engagement for a Phase 2b HIV Prevention Trial.  Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Marte S, Williams VD, Benitez J, McCrossin J, Usher D, Hammer S, Koblin B, Tieu HV, Sobieszczyk ME. Engaging Transgender Men in Biomedical HIV Prevention Research in New York City. Poster Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

Pantaleo G, Janes H, Tomaras G, Montefiori D, Frahm N, Grant S, Bart PA, Rettby N, Gonzalo T, Sinangil F, Lee C, Wagner R, Esteban M, Phogat S, Venneker E, Ding S, Tartaglia J, Corey L and Karuna S. Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04. Late-Breaker, Oral Presentation, HIVR4P, Chicago, IL, USA, October 17-21, 2016

 


file

Broder G. The Amazing World of Antibodies: secrets that could spell the end of the HIV epidemic. Oral Session, Global Village & Youth Programme at AIDS 2016, Durban, South Africa, July 18-22, 2016

Lucas J, Karuna S, Hinson K, Sista N, Yola N, Ntombela F, Mgodi N, Luthuli N, Wakefield S, Andrew P, Greene E, Delany-Moretlwe S, Gray G, White R. Engaging Community Stakeholders in Preparation for HIV Vaccine Trials Network (HVTN) 703/HIV Prevention Trials Network (HPTN) 081, an Antibody Mediated Biomedical HIV Prevention Trial in Sub-Saharan Africa. Late-Breaker, Oral Presentation, AIDS 2016, Durban, South Africa, July 18-22, 2016

Bekker LG, Laher F, Moodie Z, Tomaras G, Grunenberg N, Allen M, Daniels B, Innes C, Mngadi K, Malahleha M, Gilbert P, Michael N, Phogat S, Diaz Granados C, Kanesa-Thasan N, Corey L, Gray G, McElrath J, The HVTN 100 Study Team . Meeting the “Go”Criteria: Immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC- ® (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected South African adults. Late-Breaker, Oral Presentation, AIDS 2016, Durban, South Africa, July 18-22, 2016


Keystone Symposia

Seaton K, Mayer K, Martin J, Deal A, Goodman D, Dennison SM, Stanfield-Oakley S, Grunenberg N, Hural J, Allen M, Huang Y, Isaacs A, Mascola J, Koup R, Graham B, Corey L, Ledgerwood J, Ferrari G, Montefiori D, Tomaras G. Passively Infused VRC01 in HVTN 104 Mediates Neutralization and Antibody Effector Functions. Poster Presentation, Keystone HIV Vaccines, Olympic Valley, CA, USA, March 20-24, 2016

de Montigny S, Mâsse BR, Gilbert PB, Dimitrov DT. Projected effectiveness of mass HIV vaccination in South Africa.  Poster Presentation, Keystone HIV Vaccines, Olympic Valley, CA, USA, March 20-24, 2016

McGuire E, Fong Y, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Kunz E, McElrath MJ, Liao H-X, Haynes B, Tomaras G, Permar S and Fouda G. HIV exposed infants vaccinated with a rgp120/MF59 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine.  Poster Presentation, Keystone HIV Vaccines, Olympic Valley, CA, USA, March 20-24, 2016

Cohen KW, Imhoff DH, Simons B, DeRosa S, Frahm N, McElrath MJ. Detection and phenotyping of HIV Envelope-specific memory B cells by flow cytometry. Poster Presentation, Keystone: B Cells at the Intersections of Innate and Adaptive Immunity, Stockholm, Sweden, May 29 - June 2, 2016


file

Mayer K, Seaton K, Huang Y, Grunenberg N, Hural J, Ledgerwood J, Bailer R, Koup R, Allen M, Graham B and the HVTN 104 Protocol Team. Clinical safety and pharmacokinetics of IV and SC VRC01, a broadly neutralizing mAb. Oral Presentation, CROI 201, Boston, MA, USA, February 22-25, 2016